Karuna names Steven Paul as chief executive
UK biopharma firm PureTech Health (LSE: PRTC) has announced the appointment of Dr Steven Paul, as chief executive of its affiliate, Karuna Pharmaceuticals.
Co-founder of Karuna and former PureTech health vice president, Andrew Miller will assume the role of chief operating officer at Karuna.
Dr Paul, who also serves as chairman of the Karuna board, brings more than three decades of neuroscience and central nervous system (CNS) drug development expertise to Karuna. Previously, he spent 17 years at Eli Lilly (NYSE: LLY), in which he held several key leadership roles, including executive vice president for science and technology and president of the Lilly Research Laboratories. He is also a co-founder and board member of Sage Therapeutics (Nasdaq: SAGE), and a co-founder of Voyager Therapeutics (Nasdaq: VYGR).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze